These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 15837614)

  • 21. Progress on vaccines against parasites.
    Engers HD; Bergquist R; Modabber F
    Dev Biol Stand; 1996; 87():73-84. PubMed ID: 8854004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis.
    Duarte MC; Lage DP; Martins VT; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Goulart LR; Soto M; Tavares CA; Coelho EA
    Rev Soc Bras Med Trop; 2016; 49(4):398-407. PubMed ID: 27598624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
    Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
    Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O
    Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: how long does protection last?
    Armijos RX; Weigel MM; Romero L; Garcia V; Salazar J
    J Infect Dis; 2003 Jun; 187(12):1959-61. PubMed ID: 12792873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in vaccines for leishmaniasis.
    Requena JM; Iborra S; Carrión J; Alonso C; Soto M
    Expert Opin Biol Ther; 2004 Sep; 4(9):1505-17. PubMed ID: 15335317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leishmania transmission-blocking vaccines: a review.
    Tonui WK
    East Afr Med J; 1999 Feb; 76(2):93-6. PubMed ID: 10442130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in immune responses against Leishmania induced by infection and by immunization with killed parasite antigen: implications for vaccine discovery.
    Mendonça SC
    Parasit Vectors; 2016 Sep; 9(1):492. PubMed ID: 27600664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
    Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
    Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients.
    Rafati S; Gholami E; Hassani N; Ghaemimanesh F; Taslimi Y; Taheri T; Soong L
    Vaccine; 2007 May; 25(21):4159-69. PubMed ID: 17395340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis.
    Ravindran R; Ali N
    Curr Mol Med; 2004 Sep; 4(6):697-709. PubMed ID: 15357218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs.
    Saldarriaga OA; Travi BL; Park W; Perez LE; Melby PC
    Vaccine; 2006 Mar; 24(11):1928-40. PubMed ID: 16310897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isolation of integral membrane proteins of Leishmania promastigotes and evaluation of their prophylactic potential in hamsters against experimental visceral leishmaniasis.
    Garg R; Srivastava JK; Pal A; Naik S; Dube A
    Vaccine; 2005 Jan; 23(9):1189-96. PubMed ID: 15629362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The challenges on developing vaccine against visceral leishmaniasis.
    Jerônimo SM; Pearson RD
    Rev Soc Bras Med Trop; 2016; 49(4):395-7. PubMed ID: 27598623
    [No Abstract]   [Full Text] [Related]  

  • 36. IL-12 as an adjuvant for cell-mediated immunity.
    Scott P; Trinchieri G
    Semin Immunol; 1997 Oct; 9(5):285-91. PubMed ID: 9327523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-coding pDNA bearing immunostimulatory sequences co-entrapped with leishmanial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB/c mice.
    Mazumder S; Ravindran R; Banerjee A; Ali N
    Vaccine; 2007 Dec; 25(52):8771-81. PubMed ID: 18031874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunology of canine leishmaniasis.
    Barbiéri CL
    Parasite Immunol; 2006 Jul; 28(7):329-37. PubMed ID: 16842269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs.
    Nogueira FS; Moreira MA; Borja-Cabrera GP; Santos FN; Menz I; Parra LE; Xu Z; Chu HJ; Palatnik-de-Sousa CB; Luvizotto MC
    Vaccine; 2005 Sep; 23(40):4805-10. PubMed ID: 16011864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
    Rodríguez-Cortés A; Ojeda A; López-Fuertes L; Timón M; Altet L; Solano-Gallego L; Sánchez-Robert E; Francino O; Alberola J
    Vaccine; 2007 Nov; 25(46):7962-71. PubMed ID: 17942199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.